Drug Trial Radar · NCT06712407
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Dec 17, 2024
Primary completion
Mar 2027
Study completion Feb 2028
Sponsor
- Lead sponsor
- Asahi Kasei Therapeutics, ABIndustry
- Sponsor type
- Industry
- Collaborators
- Worldwide Clinical Trials
- First posted
- Dec 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is: Is there a treatment benefit of TARPEYO® 16 mg QD extended use? Participants will * take part in this study for about 19 months * Have urine tests done * Have blood samples taken * Have physical examinations done
Conditions
- IgA Nephropathy
Interventions
TARPEYO®Drug
6-months of TARPEYO® 16 mg QD then 9-month Treatment Period with TARPEYO® 8 mg QD and TARPEYO®4 mg QD for 2 weeks for tapering.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ratio of Urine Protein to Creatine Ratio (UPCR) at 6 months compared to BaselineTime frame: 6 months
Locations
38 sites in 2 countries. Site status is shown where the registry gives one.
Univ of Alabama/Birmingham
Birmingham, Alabama
Arizona Kidney Disease & Hypertension Centers (AKDHC)
Glendale, Arizona
The Medical Research Group, Inc.
Fresno, California
UCI Health-UCI Medical Center
Orange, California
Loma Linda University
San Bernardino, California
UCSF Health-UCSF Medical Center-Parnassus - Nephrology and Hypertension Faculty Practice
San Francisco, California
Stanford University
Stanford, California
University of Colorado Hospital (UCH) - Kidney Disease and Hypertension Clinic - Anschutz Medical Campus Location
Aurora, Colorado
Yale University Nephrology Clinical Trials Program
New Haven, Connecticut
Florida Kidney Physicians
Boca Raton, Florida
Central Florida Kidney Specialists
Orlando, Florida
Southeastern Clinical Research Institute, LLC
Augusta, Georgia
Cobb Nephrology Hypertension Associates, PC
Austell, Georgia
Georgia Nephrology
Lawrenceville, Georgia
University of Louisville
Louisville, Kentucky
Ochsner Health, New Orleans
New Orleans, Louisiana
University of Maryland Division of Nephrology
Baltimore, Maryland
Boston Medical Center; Boston University Chobanian & Avedisian School of Medicine
Boston, Massachusetts
University of Minnesota Health Fairview
Minneapolis, Minnesota
Washington University in St. Louis
St Louis, Missouri
University of New Mexico
Albuquerque, New Mexico
Renal Medical Associates
Albuquerque, New Mexico
New York Nephrology Vasculitis and Glomerular Center
Clifton Park, New York
Chinatown Kidney Care, PLLC
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
North Carolina Nephrology, P.A
Raleigh, North Carolina
Ohio State University
Columbus, Ohio
Oregon Health & Science University (OHSU) - Nephrology and Hypertension Clinic
Portland, Oregon
University of Pennsylvania Philadelphia
Philadelphia, Pennsylvania
Dallas Renal Group
Dallas, Texas
MedResearch Inc
El Paso, Texas
The University of Texas Medical Branch UTMB
Galveston, Texas
Memorial Hermann Houston
Houston, Texas
Prolato Clinical Research Center
Houston, Texas
The Kidney Institute/Houston
Houston, Texas
Dallas Nephrology Associates McKinney
McKinney, Texas
Permian Basin Kidney Center
Odessa, Texas
Advanced Renal Care Institute
Mayagüez, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.